As of 2025-07-15, the EV/EBITDA ratio of Innate Pharma SA (IPH.PA) is -3.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. IPH.PA's latest enterprise value is 149.04 mil EUR. IPH.PA's TTM EBITDA according to its financial statements is -46.80 mil EUR. Dividing these 2 quantities gives us the above IPH.PA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 1.7x - 5.8x | 2.1x |
| Forward P/E multiples | 8.7x - 11.7x | 11.3x |
| Fair Price | (4.56) - (3.08) | (3.54) |
| Upside | -409.3% - -308.8% | -340.5% |
| Date | EV/EBITDA |
| 2025-07-11 | -3.24 |
| 2025-07-10 | -3.26 |
| 2025-07-09 | -3.30 |
| 2025-07-08 | -3.26 |
| 2025-07-07 | -3.30 |
| 2025-07-04 | -3.29 |
| 2025-07-03 | -3.28 |
| 2025-07-02 | -3.28 |
| 2025-07-01 | -3.30 |
| 2025-06-30 | -3.28 |
| 2025-06-27 | -3.35 |
| 2025-06-26 | -3.33 |
| 2025-06-25 | -3.26 |
| 2025-06-24 | -3.24 |
| 2025-06-23 | -3.30 |
| 2025-06-20 | -3.41 |
| 2025-06-19 | -3.53 |
| 2025-06-18 | -3.56 |
| 2025-06-17 | -3.52 |
| 2025-06-16 | -3.55 |
| 2025-06-13 | -3.61 |
| 2025-06-12 | -3.66 |
| 2025-06-11 | -3.73 |
| 2025-06-10 | -3.80 |
| 2025-06-09 | -4.00 |
| 2025-06-06 | -4.06 |
| 2025-06-05 | -4.06 |
| 2025-06-04 | -4.08 |
| 2025-06-03 | -4.11 |
| 2025-06-02 | -4.09 |
| 2025-05-30 | -4.17 |
| 2025-05-29 | -4.19 |
| 2025-05-28 | -4.14 |
| 2025-05-27 | -4.06 |
| 2025-05-26 | -4.15 |
| 2025-05-23 | -4.15 |
| 2025-05-22 | -4.16 |
| 2025-05-21 | -4.13 |
| 2025-05-20 | -4.14 |
| 2025-05-19 | -4.10 |
| 2025-05-16 | -4.06 |
| 2025-05-15 | -4.06 |
| 2025-05-14 | -4.13 |
| 2025-05-13 | -4.20 |
| 2025-05-12 | -4.24 |
| 2025-05-09 | -4.31 |
| 2025-05-08 | -4.37 |
| 2025-05-07 | -4.26 |
| 2025-05-06 | -4.07 |
| 2025-05-05 | -4.04 |